There is an ongoing global effort to design, manufacture, and clinically assess vaccines against SARS-CoV-2. Over the course of the ongoing pandemic a number of new SARS-CoV-2 virus isolates or variants of concern (VoC) have been identified containing mutations in key proteins. In this study we describe the generation and preclinical assessment of a ChAdOx1-vectored vaccine (AZD2816) which expresses the spike protein of the Beta VoC (B.1.351). We demonstrate that AZD2816 is immunogenic after a single dose. When AZD2816 is used as a booster dose in animals primed with a vaccine encoding the original spike protein (ChAdOx1 nCoV-19/ [AZD1222]), high titre binding and neutralising antibodies against Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) are induced. In addition, a strong and polyfunctional T cell response was measured in these booster regimens. These data support the ongoing clinical development and testing of this new variant vaccine.

中文翻译：

---

ChAdOx1 载体疫苗 AZD2816 可诱导针对 SARS-CoV-2 Beta (B.1.351) 和其他临床前研究中关注的变体的强免疫原性

全球正在努力设计、制造和临床评估针对 SARS-CoV-2 的疫苗。在持续的大流行过程中，已经发现了许多新的 SARS-CoV-2 病毒分离株或关注变种 (VoC)，其中包含关键蛋白质的突变。在本研究中，我们描述了表达 Beta VoC (B.1.351) 刺突蛋白的 ChAdOx1 载体疫苗 (AZD2816) 的生成和临床前评估。我们证明 AZD2816 在单次给药后具有免疫原性。当 AZD2816 用作动物的加强剂量时，该动物接种了编码原始刺突蛋白 (ChAdOx1 nCoV-19/ [AZD1222])、针对 Beta (B.1.351)、Gamma (P.1) 的高滴度结合和中和抗体和 Delta (B.1.617.2) 被诱导。此外，在这些加强方案中测量到了强大的多功能 T 细胞反应。这些数据支持正在进行的这种新型变异疫苗的临床开发和测试。